Spots Global Cancer Trial Database for First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
Official Title: Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-line Therapy of Metastatic or Locally Advanced Pancreatic Cancer
Study ID: NCT00673504
Conditions
Study Description
Brief Summary: Primary objective: to evaluate whether the addition of sunitinib prolongates the Progression-Free Survival (PFS) in patients with advanced pancreatic cancer receiving first-line gemcitabine chemotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Städtisches Klinikum Braunschweig, Braunschweig, , Germany
Universitätsklinikum Essen, Essen, , Germany
Krankenhaus, Frankfurt, , Germany
Klinikum der J. W. Goethe Universität; Zentrum der Inneren Medizin, Frankfurt, , Germany
Internistisches Facharztzentrum, Frankfurt, , Germany
Martin-Luther-Universität Halle-Wittenberg; Medizinische Fakultät, Halle (Saale), , Germany
Facharztpraxis, Heidelberg, , Germany
Klinikum Lüdenscheid, Luedenscheid, , Germany
Klinikum Nürnberg Nord, Nürnberg, , Germany
Robert-Bosch-Krankenhaus, Stuttgart, , Germany
Kantonsspital St. Gallen, St. Gallen, , Switzerland
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
